SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Jazz Pharmaceuticals To Present New Data On Xywav Oral Solution And Sunosi At Virtual SLEEP 2020

DUBLIN, Aug. 27, 2020 /PRNewswire/ --Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that 10 abstracts will be presented at Virtual SLEEP 2020, the 34th annual meeting of the Associated Professional

 · 

DUBLIN, Aug. 27, 2020 /PRNewswire/ --Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that 10 abstracts will be presented at Virtual SLEEP 2020, the 34th annual meeting of the Associated Professional Sleep Societies (APSS) from August 28-30. The presentations will debut data across Jazz's neuroscience therapeutic area, featuring important new insights into the company's ongoing sleep medicine research.

"At Jazz, we understand that sleep disorders can impact everyday life, which is why we are focused on identifying and developinginnovative therapies for people with serious sleep disorders," said Robert Iannone, M.D., M.S.C.E., executive vice president, research and development of Jazz Pharmaceuticals. "Our goal is to think more holistically about patients' health so they can live fuller lives and our purpose is to innovate to transform the lives of patients. We are proud to present research at SLEEP on our meaningful therapeutic options for these patients with lifelong, chronic sleep disorders."

Highlights from Jazz at Virtual SLEEP 2020 will include the following presentations on Xywav™ (calcium, magnisium, potassium and sodium oxybate) oral solution (JZP-258), a lower sodium oxybate (LXB) indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy:

  • Three poster presentations from the Phase 3, placebo-controlled, double-blind, randomized withdrawal study of JZP-258 in adults with narcolepsy with cataplexy
    • Abstract 0740: Analysis of patients' health-related quality of life
    • Abstract 0752: Findings on dose titration and transition from sodium oxybate
    • Abstract 0753: Cataplexy-free days analysis

The company will also feature two poster presentations on the effects of Sunosi®(solriamfetol) on driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy.

The Virtual SLEEP 2020 presentations and exhibit hall are available 24 hours a day for registered attendees from August 28-30 at www.sleepmeeting.org.